Drugs / JT118
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07495202 | May 2026 → Nov 2027 expected | — | Shanghai JunTop Biosciences Co., LTD | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JT118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07495202 ↗ |
| Modality | Protein / enzyme biologic | “Monkeypox recombinant protein vaccine JT118” NCT07495202 ↗ |
| Route | Subcutaneous | “The vaccine was administered by Subcutaneous Injection” NCT07495202 ↗ |